Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

992 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study.
Thomson MJ, Serper M, Khungar V, Weiss LM, Trinh H, Firpi-Morell R, Roden M, Loomba R, Barritt AS 4th, Gazis D, Mospan AR, Fried MW, Reddy KR, Lok AS. Thomson MJ, et al. Among authors: reddy kr. Clin Gastroenterol Hepatol. 2022 Feb;20(2):458-460.e4. doi: 10.1016/j.cgh.2021.03.031. Epub 2021 Mar 26. Clin Gastroenterol Hepatol. 2022. PMID: 33775894 Free PMC article.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Fried MW, et al. Among authors: reddy kr. N Engl J Med. 2002 Sep 26;347(13):975-82. doi: 10.1056/NEJMoa020047. N Engl J Med. 2002. PMID: 12324553 Free article. Clinical Trial.
Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial.
Pockros PJ, Carithers R, Desmond P, Dhumeaux D, Fried MW, Marcellin P, Shiffman ML, Minuk G, Reddy KR, Reindollar RW, Lin A, Brunda MJ; PEGASYS International Study Group. Pockros PJ, et al. Among authors: reddy kr. Am J Gastroenterol. 2004 Jul;99(7):1298-305. doi: 10.1111/j.1572-0241.2004.30306.x. Am J Gastroenterol. 2004. PMID: 15233669 Clinical Trial.
Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease.
Dickson RC, Terrault NA, Ishitani M, Reddy KR, Sheiner P, Luketic V, Soldevila-Pico C, Fried M, Jensen D, Brown RS Jr, Horwith G, Brundage R, Lok A. Dickson RC, et al. Among authors: reddy kr. Liver Transpl. 2006 Jan;12(1):124-33. doi: 10.1002/lt.20582. Liver Transpl. 2006. PMID: 16382463 Free article. Clinical Trial.
992 results